Roche Racks Up Another RoActemra Green Light To Boost Revenues
The Swiss giant's blockbuster is the first non-steroid therapy approved in Europe for giant cell arteritis and the first major advance in treatment for over 50 years.
You may also be interested in...
Roche’s Gazyvaro is the fifth drug to be recommended by UK HTA body NICE for use on an interim fund that gives manufacturers more time to gather evidence to prove their drugs are cost-effective and win long-term funding on the National Health Service.
Keeping Track: Immunology In Focus As US FDA Approves Kevzara, New Breakthrough Actemra Use; J&J, Sun Advance Psoriasis Candidates
The latest immunology drug development news and highlights from our FDA Performance Tracker.
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.